Additional diagnostic value of the monocyte to red blood cell count ratio and the product of lymphocyte count and albumin concentration in lung cancer management

Chen, Xinxin; Shu, Zhao; Yang, Xian-Miao; He, Shan-Chuan; Qian, Fen-Hong

doi:10.3892/ol.2023.13721

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In lung cancer patients, Chen et al confirmed lower LA levels compared to a healthy control group, and as the disease advanced, LA levels demonstrated a declining trend. Consequently, LA arises as a prospective supplementary biomarker for the diagnosis of lung cancer and may partially signify the progression of the disease [32]. Theoretically, our novel prognostic marker "LA" shares similarities with PNI; however, LA offers the advantage of being a more straightforward calculation, which can provide opportunities for further clinical practice.…”

Section: Discussionmentioning

confidence: 99%

A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study

Wang,

Duan,

Hua

et al. 2023

Nutrients

View full text Add to dashboard Cite

Background: Recently, there has been a growing focus on the prognostic significance of nutrition-related biomarkers. We attempted to explore the association between a novel albumin-related nutrition marker called “lymphocyte × albumin (LA)” and disease-free survival (DFS) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Methods: In total, 711 non-metastatic breast cancer patients who underwent NAC at two medical centers were retrospectively analyzed. We performed least absolute shrinkage and selection operator (LASSO) Cox regression analysis as well as multivariate Cox regression analyses to identify the variables associated with DFS and to establish a predictive nomogram. Results: The nomogram incorporated four variables based on the multivariate analysis of DFS in the training cohort: LA, ypN stage, ypT stage, and hormone receptor status. In comparison with the traditional TNM staging system, the nomogram demonstrated superior discrimination, calibration ability, and clinical usefulness in both the training set and internal and external validation sets. Furthermore, patients stratified into different risk groups resulted in significant differences in DFS. Conclusions: LA is an independent prognostic biomarker, and LA-based prognostic nomogram offers a more precise assessment of DFS for breast cancer patients treated with NAC, potentially serving as a valuable tool for personalized prognostic predictions.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study

Wang,

Duan,

Hua

et al. 2023

Nutrients

View full text Add to dashboard Cite

show abstract

A combination of lymphocyte count and albumin concentration as a new prognostic index for Hepatocellular Carcinoma

Sarıtaş,

Topal,

Yavuz

et al. 2024

Balıkesir Medical Journal

View full text Add to dashboard Cite

Aim The present study explores the prognostic significance of the lymphocytes (/L) × albumin (g/L) (LA) score and its relationship with the hepatocellular carcinoma. Material and Methods The study included patients who underwent curative surgery for hepatocellular carcinoma between January 2004 and November 2020. The LA score was calculated using the formula lymphocytes (/L)×albumin (g/L). The patients were subsequently divided into two as Group 1 (Low LA) and Group 2 (High LA). The two groups were compared for clinical characteristics as well as oncological follow-up outcomes. Results The study included 55 patients, who, based on an LA cut-off point of 4620, were divided into Group 1 (n=28) and Group 2 (n=27). The MELD score was higher in Group 1 (12 vs.9, p=0.022). The number of tumors, maximum tumor size and total tumor size were similar in both groups. At the last clinical follow-up, the mortality rate was 42.9% in Group 1 and 22.2% in Group 2. Recurrence rates were similar in both groups (42.9%vs.33.3% p=0.467), and total survival (126vs.164 months p=0.1) and disease-free survival (26 vs. 29 months p=0.926) were also similar. Conclusion The use of the composite LA index – an indicator of immunonutritional status as a prognostic marker may not be significant in HCC patients undergoing curative resection.

show abstract

A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Yildirim,

Dogan,

Akdag

et al. 2024

Cancers

View full text Add to dashboard Cite

Objective: Immunotherapies are commonly employed for the treatment of non-small-cell lung cancer (NSCLC). However, predictive biomarkers still need to be improved to predict responses to these agents. The lymphocyte–albumin (LA) laboratory index has not been evaluated before in this patient group. The aim of this study was to analyze the relation between the LA index and the survival rate of metastatic NSCLC patients who had immunotherapy after at least one round of chemotherapy. Methods: The research included 227 patients diagnosed with metastatic NSCLC, who were administered nivolumab after at least one round of chemotherapy. The LA index was calculated by multiplying lymphocyte count and albumin concentration. The optimal threshold values for the index were established by the examination of the ROC curve for both overall survival (OS) and progression-free survival (PFS). Oncological data were obtained retrospectively from patient files, and survival analyses were performed. Results: The median follow-up was 7.9 months. Progression was observed in 129 (56.9%) patients. A total of 97 (42.7%) patients died during the follow-up. The cutoff values of the LA index to predict OS and PFS were determined as 52.87 and 57.67, respectively. The low-LA group had significantly lowered OS and PFS compared to the high-LA group. LA was found to be an independent prognostic factor for PFS (hazard ratio 4.47; 95% confidence interval, 2.73–7.34; p < 0.001) and OS (hazard ratio 6.24; 95% confidence interval, 3.46–11.25; p < 0.001) in the multivariate regression analysis. Conclusions: In this study, we observed that the LA index independently predicts OS and PFS in immunotherapy-treated metastatic NSCLC patients. Its ease of application, low cost, and noninvasive nature make it a potential guide for clinicians in predicting treatment responses and survival.

show abstract

Additional diagnostic value of the monocyte to red blood cell count ratio and the product of lymphocyte count and albumin concentration in lung cancer management

Cited by 3 publications

References 34 publications

A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study

A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study

A combination of lymphocyte count and albumin concentration as a new prognostic index for Hepatocellular Carcinoma

A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Contact Info

Product

Resources

About